David Kirn - Dec 11, 2023 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role: Chief Executive Officer, Director
Signature: By: /s/ Scott Bizily as Attorney-in-fact David Kirn
Stock symbol: FDMT
Transactions as of: Dec 11, 2023
Transactions value $: $0
Form type: 4
Date filed: 12/13/2023, 04:05 PM
Previous filing: May 4, 2023
Next filing: Jan 8, 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FDMT	Stock Option (Right to Buy)	Award	$0	+590K		$0.00	590K	Dec 11, 2023	Common Stock	590K	$14.42	Direct	F1

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Content

The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.